BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934
Phase 2
Completed
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- Biological: Darbepoetin alfa
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 126
- Registration Number
- NCT02021409
- Locations
- 🇹🇷
Baskent University Medical Faculty, Ankara, Turkey
🇹🇷Ankara Univ. Medical Faculty, Ankara, Turkey
🇹🇷Sifa University Medical Faculty, Izmir, Turkey
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 61
- Registration Number
- NCT02007629
Effect of Neomycin on the Pharmacokinetics of Regorafenib
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT02001909
Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 61
- Registration Number
- NCT01982097
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 168
- Registration Number
- NCT01976741
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Phase 2
Completed
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- Biological: Epoetin alfa/beta
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 201
- Registration Number
- NCT01975818
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT01973868
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 89
- Registration Number
- NCT01971450
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
Phase 2
Completed
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: BAY94-8862Drug: PlaceboDrug: BAY 94-8862
- First Posted Date
- 2013-10-24
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 96
- Registration Number
- NCT01968668
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
Phase 3
Completed
- Conditions
- Skin Diseases, Infectious
- Interventions
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 125
- Registration Number
- NCT01967225
© Copyright 2025. All Rights Reserved by MedPath